Health News

Threshold Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1/2 clinical trial in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented at the European Society for Medical Oncology (ESMO) Annual Meeting being held in Milan, Italy.

Read more

Filed under: Pharmacy News
Tags: Oncology, Pharmacy, Tumor

Related posts

• ZIOPHARM receives European patent allowance for palifosfamide to treat cancer (0)
  ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer. Read more [tags] Pharmacy [...]
  
  
• ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco. Read [...]
  
  
• Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers (0)
  A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology. Read [...]
  
  
• Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer (0)
  Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target. Read more [tags] Pharmacy News [/tags]
  
  
• Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors (0)
  Synta Pharmaceuticals Corp. announced that results of a Phase 1 study of ganetespib in combination with docetaxel in solid tumors were presented at the Annual Meeting of the European Society of Medical Oncology in Stockholm, Sweden. Read more [tags] Pharmacy News [/tags]